Related Experiment Video

Updated: Aug 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

LINC01082 Inhibits Non-Small Cell Lung Cancer by Targeting the miR-543/TNRC6A Axis

Ran Yang1,2, Jinli Han3, Song Zhao4

  • 1Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450052, Henan, China.

Biochemical Genetics
|January 31, 2023
PubMed

Insights

Long non-coding RNA LINC01082 suppresses non-small cell lung cancer (NSCLC) by inhibiting proliferation, migration, and invasion. It acts as an antioncogene by interacting with miR-543 to regulate TNRC6A expression in NSCLC.

Area of Science:

  • Molecular Oncology
  • Cancer Biology
  • Non-coding RNA Research

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths with poor outcomes.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
  • LINC01082 has been found to be downregulated in various cancer types.

Purpose of the Study:

  • To investigate the role of LINC01082 in the development of NSCLC.
  • To elucidate the molecular mechanism of LINC01082 in NSCLC, including its interactions with miR-543 and TNRC6A.

Main Methods:

  • Bioinformatic analysis of LINC01082, miR-543, and TNRC6A expression in NSCLC.
  • RT-qPCR to quantify gene and miRNA expression.
  • In vitro assays (MTT, EdU, Transwell, flow cytometry) to assess cell proliferation, migration, invasion, and apoptosis.
  • RNA pulldown and luciferase reporter assays to confirm molecular interactions.

Main Results:

  • LINC01082 expression was significantly downregulated in NSCLC tissues and cells.
  • Overexpression of LINC01082 inhibited NSCLC cell proliferation, migration, and invasion, while promoting apoptosis.
  • LINC01082 directly targets miR-543, which in turn targets TNRC6A. TNRC6A was downregulated and miR-543 overexpressed in NSCLC.
  • Inhibition of miR-543 suppressed malignant behaviors, and TNRC6A knockdown reversed the antioncogenic effects of LINC01082.

Conclusions:

  • LINC01082 functions as a tumor suppressor in NSCLC.
  • The LINC01082/miR-543/TNRC6A axis plays a critical role in regulating NSCLC progression.
  • LINC01082 may serve as a potential therapeutic target for NSCLC.
Keywords:
LINC01082Non-small cell lung cancerTNRC6AmiR-543

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.4K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K